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Abstract
Introduction and hypothesis Stress urinary incontinence
(SUI) is a common and growing problem among adult women
and affects individuals and society through decreased quality
of life (QoL), decreased work productivity, and increased
health care costs. A new, nonsurgical treatment option has
become available for women who have failed conservative
therapy, but its cost effectiveness has not been evaluated. This
study examined the cost effectiveness of transurethral
radiofrequency microremodeling of the female bladder neck
and proximal urethra compared with synthetic transobturator
tape (TOT), retropubic transvaginal tape (TVT) sling, and
Burch colposuspension surgeries for treating SUI.
Methods A Markov model was used to compare the cost
effectiveness of five strategies for treating SUI for patients
who had previously failed conservative therapy. The strategies
were designed to compare the value of starting with a less
invasive treatment. The cost-effectiveness analysis was
conducted from the health care system perspective. Efficacy
and adverse event rates were obtained from the literature;
reimbursement costs were based on Medicare fee schedule.
The model cycle was 3 months, with a 3-year time horizon.
Single-variable sensitivity analyses were conducted to assess
stability of base-case results.
Results Two of the five strategies employed the use of trans-
urethral radiofrequency microremodeling and achieved 17–
30 % lower mean costs relative to their comparative sling or
Burch strategies.
Conclusions Superior safety and cost effectiveness are recog-
nized when patients are offered a sequential approach to SUI
management that employs transurethral radiofrequency
microremodeling before invasive surgical procedures. This
sequential approach is consistent with treatment strategies
for other conditions and offers a solution for women with
SUI who want to avoid the inherent risks and costs of invasive
continence surgery.
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Introduction
Stress urinary incontinence (SUI), the most common form of
UI, is defined by involuntary leakage of urine with effort,
exertion, sneezing, or coughing [1]. Traditional surgical treat-
ments include Burch colposuspension and autologous
bladder-neck slings using rectus fascia, both of which have
been used for many years. Subsequently, synthetic
transobturator tape (TOT) and retropubic transvaginal tape
(TVT) sling materials were introduced in kits, continuing to
facilitate changing surgical approaches to SUI.
Recently, the US Food and Drug Administration (FDA)
cleared a nonsurgical alternative developed for treating SUI.
The Lyrette System™ was developed by Novasys Medical,
Newark, CA, USA, and acquired by Verathon, Inc., Bothell,
WA, USA. The procedure is referred to in this article as RF-
SUI: radiofrequency for stress urinary incontinence. This
treatment uses a disposable RF probe that a physician passes
through the urethra. RF energy is then used to generate
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controlled heat at low temperatures in tissue targets within the
bladder neck and urethra. The heat denatures collagen in the
tissue at the multiple treatment sites. Upon healing, the treated
tissue demonstrates an increased resistance to involuntary
leakage at times of heightened intra-abdominal pressure,
thereby reducing or eliminating SUI episodes. RF-SUI can
be performed in a physician’s office or other outpatient
setting.
Safety and efficacy of the RF-SUI procedure was demon-
strated in three multicenter clinical trials [2–5]. Those trials
indicated that RF collagen denaturation was not associated
with any major adverse events (AE) and provided durable
efficacy. In a blinded trial, 110 women were randomized to
RF-SUI treatment and 63 to a sham treatment. After 12-month
and 3-year follow-up, women with moderate to severe SUI
reported greater increase (improvement) in Incontinence
Quality of Life score compared with women who received
the sham treatment [2, 3]. In a prospective single-arm trial,
136 women were treated with RF-SUI and followed for 3
years, more than 60 % of whom reported improved QoL and
reduced symptoms, which continued through the follow-up
period [4].
The introduction of a nonsurgical alternative to the treat-
ment armamentarium for SUI offers one more option for
physicians and patients. Although surgical and nonsurgical
treatments are effective, some patients require multiple
procedures before reaching clinical success as defined by dry
rates. In this paper, we define a strategy as an intentionally
staged series of treatments for SUI. The strategies were
constructed to compare the costs and effectiveness of starting
with a less invasive treatment versus starting with a surgical
treatment.
Cost-effectiveness analysis has been used to compare in-
terventions and provide decision support to identify which
intervention offers good value for the money compared with
alternatives. It is especially valuable when intervention strat-
egies consist of multiple paths and multiple treatments over
several years. RF-SUI treatment has lower costs and is
associated with fewer serious AE (SAE) than surgical
treatments, but clinical trials have shown that it is also
associated with lower efficacy. Therefore, it is not clear
whether the savings associated with RF-SUI in the short
term will be maintained after several years, when sub-
sequent SUI recurrence may require additional treat-
ment. Cost-effectiveness models can incorporate the re-
sults of numerous randomized controlled trials (RCTs)
to develop a broader picture of alternative strategies and
their potential costs and effects. In this study, we developed a
cost-effectiveness model to compare RF-SUI strategies to
alternative surgical strategies for women with SUI who had
failed conservative treatment. We report findings from the
literature review for model inputs, the base case analysis,
and sensitivity analysis.
Materials and methods
This study was an economic analysis with variable estimates
from the literature. The study did not involve humans. Internal
review board approval was not required. A Markov micro-
simulation model was developed to compare costs and effec-
tiveness of five strategies for treating SUI. AMarkov model is
defined by a number of discrete health states, transition paths
between states, transition cycle time, and total time horizon. A
microsimulation projects a hypothetical patient along the tran-
sition paths to defined health states for the duration of the
projection. In this study, a patient begins the simulation with a
treatment for SUI and can then experience AE, treatment
success, treatment failure, and subsequent treatments. Costs
and effects for each patient are assigned during each cycle and
accumulated over the duration of the projection and over all
simulated patients. The model evaluated RF-SUI strategies to
surgical strategies for women with SUI who had failed con-
servative therapy. Two RF-SUI strategies, two sling strategies,
and one Burch strategy was defined (Table 1). RF-SUI Awas
compared with Sling strategy A and Sling strategy B; RF-SUI
strategy B was compared with Burch.
The strategies were developed based on the prevailing
philosophy of the medical community and the American
Urological Association (AUA) that care providers offer effi-
cacious therapies and that first-line treatment should be con-
servative. If initial, conservative treatments fail, more invasive
treatments may be considered. All simulated patients in this
analysis were assumed to have failed conservative treatment.
The RF-SUI procedure is minimally invasive and nonsurgical.
We developed strategies to compare the costs and effects of








RF-SUI strategy A RF-SUI TVT (40 %) TVT (50 %
TOT (60 %) Traditional (50 %)
Sling strategy A TVT (40 %) TVT (50 % Traditional
Traditional
(50 %)
TOT (60 %) TVT Traditional
Sling strategy B TVT (40 %) Burch Burch
TOT (60 %)
RF-SUI strategy B RF-SUI Burch TVT (40 %)
TOT (60 %)
Burch strategy Burch TVT (40 %) TVT (50 %
TOT (60 %) Traditional (50 %)
RF-SUI radiofrequency for stress urinary incontinence, TVT retropubic
midurethral synthetic sling, TOT transobturator midurethral synthetic
sling, Traditional bladder-neck autologous sling, Burch Burch
colposuspension
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using the RF-SUI treatment with strategies starting with a
surgical intervention. The subsequent treatment in each strat-
egy was based on practice patterns in North America. For a
patient who failed RF-SUI, most surgeons would proceed to a
minimally invasive procedure, such as a midurethral sling.
Because some surgeons or patients have concerns about com-
plications associated with synthetic mesh, they may proceed
directly to a Burch procedure. When midurethral slings fail, it
is often due to intrinsic sphincter insufficiency, which would
lead the surgeon to recommend retropubic midurethral slings.
Should retropubic slings fail, it could be due to a lack of
urethral hypermobility or significant sphincter insufficiency.
Most surgeons would follow a failed retropubic sling with a
traditional autologous bladder-neck sling.
Model structure
For each treatment strategy, outcomes for 100,000 simulated
patients were estimated over a 3-year time horizon in quarterly
cycles. Patients entering the model were assumed to have
failed previous conservative treatment for SUI. At the begin-
ning of each simulation, patients received the primary treat-
ment as defined by the strategy. At each subsequent cycle, the
patient could follow one of four paths: (1) experience an SAE,
(2) experience a minor adverse event, (3) experience treatment
failure, or (4) continue with ongoing monitoring of care.
Transition probabilities were based on published evidence;
the proportion of TVT and TOT treatments was assumed to
be 40 % and 60 %, respectively, based on experience of the
first author. AE incurred treatment costs and returned to treat-
ment follow-up in the next cycle. Treatment failures were
followed by secondary or tertiary treatment, as shown in
Table 1. This is a worst-case scenario of retreatment and
therefore of costs. In actual clinical practice, not all patients
who experience treatment failure as measured by pad-weight
testing seek additional therapy. Effectiveness was measured
by the number of quarters in which primary treatment
maintained efficacy or the end of the simulation. Costs were
evaluated from the perspective of the health care system and
included reimbursement to hospitals and physicians for
treating SUI, treating AE, and follow-up care. Indirect costs
for patient time were not considered. Costs and outcomes
were recorded at each cycle of the simulation and discounted
at an annual rate of 5 %. The model was developed using
TreeAge Pro 2012 (TreeAge Software, Inc., Williamstown,
MA, USA).
Model inputs
Model inputs were identified from the literature. Key assump-
tions in the model were treatment efficacy, AE associated with
treatment, and health care costs of treatment and AE. The
purpose of the analysis was to compare costs and effects of
the defined treatment strategies; therefore, efficacy, AE, and
cost assumptions were carefully evaluated. Literature sources
for estimates of treatment efficacy and incidence of AE were
identified through a MEDLINE search and references from
Cochrane Reviews of surgical treatment for SUI [6, 7]. Pad
test was selected as the efficacy measure because it was the
most consistently reported measure across studies. Estimates
of AE were taken from recent multicenter RCTs of SUI
treatment, which provided complete AE reporting [2, 4,
8–13]. AE that resulted in additional health care costs were
included in the incidence rate. AE that occurred intraopera-
tively, were unrelated to treatment, or were not defined spe-
cifically enough to identify treatment were excluded. Loss of
efficacy and AE incidence from each study were converted to
quarterly rates assuming a standard exponential distribution.
Rates were averaged across studies weighted by number of
patients. Studies were excluded if they contained patients with
intrinsic sphincter deficiency or urgency urinary incontinence
(UUI), reported <12 month of follow-up, were not written in
the English language, or were reported in an Abstract only.
Studies that did not report efficacy based on pad test were also
excluded.
All payments were based on the Medicare 2012 fee sched-
ule allowance. RF-SUI procedures were assumed to be
performed as an office visit; sling procedures were assumed
to be performed as outpatient—one third in ambulatory sur-
gery centers and two thirds in hospital outpatient facilities; and
Burch surgeries were assumed to be performed as hospital
inpatient only. Ambulatory surgical centers are free-standing
facilities that provide same-day surgical care and are an alter-
native to hospital outpatient facilities. Follow-up office visits
were assumed to occur 6-months and 12-months postprocedure
and annually thereafter. Average costs for treating serious and
minor AE were estimated for each SUI treatment. Types and
numbers of events were identified from the literature [2,
4, 8–13]. The average cost for treating serious and minor AE
was weighted by the number of events reported.
Sensitivity analysis
Single-variable sensitivity analyses were used to assess stabil-
ity of base-case results. The simulation was repeated using a
range of values for key variables, and results were compared
with those from the base case. The lower and upper limits of a
normal 95 % confidence interval (CI) were used to evaluate
sensitivity to efficacy and AE rates. Costs for procedures and
treating AE were assumed to range ±10 % of base case for RF-
SUI and from +20 % to −10 % of base case for the other
treatments. The difference in range was due to the complexity
of the treatments. RF-SUI is a relatively simple treatment with
no facility or independent anesthesiology expenses. The com-
plexity of the other treatments warranted higher variable costs
because of the additional input costs from ambulatory surgery
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centers, hospitals, postoperative pain management, and region-
al variations in physician utilization of ancillary resources.
Results
Literature review
Eight articles representing seven studies were included for
estimates of treatment efficacy (Table 2) [4, 9, 11, 12,
14–17]. Efficacy measured by pad test ranged from 35% over
a 36-month period [4] to 92 % over a 12-month period [12].
Four studies used a 1-h pad test and defined dry as <1 or <2 g,
one used a 20-min pad test, and two used a 24-h pad test.
Three studies had follow-up periods of 12 months; the others
measured outcomes at 24, 36, or 60 months.
Serious and minor AE rates were estimated from five
studies [2, 4, 8–13]. The most common SAEs resulting in
additional costs were voiding dysfunction leading to surgical
revision, wound complication requiring surgical intervention,
mesh exposure or erosion, and recurrent cystitis leading to
diagnostic cystoscopy. Cystitis and wound complication not
requiring surgical intervention were common minor AE.
Base case
Base-case assumptions for each SUI treatment are shown in
Table 3. Annual loss-of-efficacy rates for sling treatments and
Burch surgery were similar at 7–10 %. The rate for RF-SUI
was 35 %; however, the annual minor AE rate was lower than
all other treatments, and the annual SAE rate was zero. Burch
surgery and traditional slings had the highest rates of minor
AE; TVT, traditional slings, and Burch surgery had the highest
rates of SAEs at 3– 6 %.
Procedure costs for RF-SUI were less than one half the cost
of sling treatments and were one fifth the cost of Burch
surgery. Average treatment costs for SAEs were similar for
sling and Burch surgery. Average treatment costs for minor
AE were lowest for RF-SUI and traditional slings and highest
for TVT and TOT slings. The cost of follow-up office visits
was assumed to be the same for all SUI treatments.
Results of the base-case simulation for the five strategies are
shown in Table 4. Compared with the sling strategies, RF-SUI
strategy A had the lowest average costs over the 3-year period
($4,102), 17% lower than Sling strategyA and 29% lower than
Sling strategy B. Compared with the Burch strategy, RF-SUI
strategy B had 30 % lower average costs over the 3-year period
($6,579). The average duration of primary treatment efficacy
was 8 quarters for both of the RF-SUI strategies and 11 quarters
for the Sling and Burch strategies, with the maximum of 12
quarters. At the end of the 3-year simulation, about 80 % of
sling and Burch strategy patients had not received secondary
treatment: 36 % of RF-SUI strategy patients had not received
secondary treatment. Less than 3 % of patients in the RF-SUI
strategy A or B groups experienced an SAE; more than three
times that number experienced SAEs in the other strategies.
Sensitivity analysis
In the sensitivity analysis, efficacy and procedure costs were
the most influential on total costs. AE rates and cost had little
impact on results. When all treatments were at their upper or
lower limit of efficacy, the relative ranking of strategies by
mean cost did not change from the base case. RF-SUI strategy
A ($2,970 upper limit; $4,973 lower limit) was lower than
sling A ($4,477; $5,427) and B ($4,765; $6,809) strategies.
RF-SUI strategy B ($4,347; $8,146) was lower than the Burch
strategy ($8,989; $9,897). When RF-SUI was at the upper
limit of efficacy and the other treatments were at their lower
limits, RF-SUI strategies were 43–55 % less expensive than
the comparative sling and Burch strategies. When RF-SUI
was at its lower limit of efficacy and the other treatments were
at their upper limits, costs of RF-SUI strategies remained
Table 2 Efficacy estimates from reviewed literature
Pad test
Efficacy Patients Follow-up period
Transurethral radiofrequency energy collagen microremodeling
Elser 2011 [4] 35%a 136 36 months
TVT, retropubic midurethral synthetic sling
Liapis 2002 [14] 84%b 36 24 months
Liapis 2006 [15] 89%b 46 12 months
Richter 2010 [12] 92.3%c 298 12 months
Wang 2003 [16] 81.6%d 49 12 months
Ward 2004 [11] 77.7%b 175 24 months
Ward 2007 [17] 74.9%b 175 5 years
TOT, transobturator midurethral synthetic sling
Liapis 2006 [15] 90%b 43 12 months
Richter 2010 [12] 93%c 299 12 months
Burch colposuspension surgery
Albo 2007 [9] 85%c 255 24 months
Liapis 2002 [14] 86%b 35 24 months
Ward 2004 [11] 68%b 169 24 months
Ward 2007 [17] 69%b 169 5 years
Traditional bladder-neck autologous sling
Albo 2007 [9] 86%c 265 24 months
Two- and 5-year results from Ward 2004 and Ward 2007 were interpo-
lated to estimate a 3-year measure for modeling
a 20-min pad test, dry pad measured as <1 g
b 1-h pad test, dry pad measured as <1 g
c 24-h pad test, dry pad measured as <15 g
d 1-h pad test, dry pad measured as <2 g
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lower compared with Sling strategy B and Burch, but RF-SUI
strategy Awas 4 % higher than Sling strategy A. Comparing
across strategies at the upper limits of procedure cost
maintained the relationship found in the base-case analysis.
RF-SUI strategies were 19–31 % lower in mean cost relative
to their comparative sling or Burch strategies.
Discussion
This study compares the costs and effectiveness of five strat-
egies used to treat female SUI. Comparisons are between the
less invasive, office-based RF-SUI and commonly used sur-
gical interventions such a midurethral slings (TVT or TOT)
and retropubic colposuspensions (Burch). Although the AUA
and the International Urogynecological Association (IUGA)
[18] have proposed standards for reporting efficacy and out-
comes in SUI trials, these standards have not been universally
adopted and used in many trials frequently referenced in the
SUI literature. Given the variety of outcome definitions used
to define success across a multitude of SUI studies, we select-
ed pad weight as the objective outcome, as this is thought to be
the most consistent measurement used across the studies
referenced in this paper.
It should be understood that measuring efficacy only in
terms of outcomes does not represent the fully burdened cost
of treatment because it does not incorporate costs of potential
complications. The addition of costs associated with manag-
ing SAEs in each treatment arm was therefore included in this
analysis. The materiality of such costs impacting the short-
and long-term management of such SAEs serves to offset
some of the qualitative and quantitative success rates associ-
ated with the use of the different treatment modalities. The
addition of such AE costs are thought to be a valuable contri-
bution to payers in light of the differences noted in the SAE
profiles among the treatment strategies discussed.
Table 3 Base-case assumptions
Annual rates Reimbursement costs
Treatment Loss of efficacy Minor AE Serious AE Procedure Minor AE Serious AE
RF-SUI 0.350 0.135 0.000 $1,571.74 $57.55
TVT synthetic 0.096 0.391 0.052 $3,735.84 $154.79 $3,754.13
TOT synthetic 0.077 0.159 0.017 $3,735.84 $138.27 $2,999.04
Burch surgery 0.097 0.899 0.037 $8,061.10 $68.56 $3,235.48
Traditional sling 0.075 0.890 0.062 $3,735.84 $57.55 $2,981.99
AE adverse events, RF-SUI radiofrequency for stress urinary incontinence, TVT retropubic midurethral synthetic sling, TOT transobturator midurethral
synthetic sling, Traditional bladder-neck autologous sling
Follow-up office visit reimbursement $42.44 for all treatments
Table 4 Simulation results; comparison of treatment strategies
Strategies Mean cost Average duration of primary
treatment, quartersa, max=12
Percent still on primary
procedure at 3 years
Percent with
SAEs at 3 years
RF-SUI strategy A $4,102 8 36 % 2.4 %
Sling strategy A $4,962 11 79 % 8.3 %
Sling strategy B $5,807 11 79 % 8.0 %
RF-SUI strategy B $6,579 8 36 % 2.9 %
Burch strategy $9,450 11 76 % 9.3 %
Initial Secondary Tertiary
RF-SUI strategy A RF-SUI→ TVT or TOT→ TVT or traditional
Sling strategy A TVT or TOT→ TOT or traditional or TVT→ Traditional
Sling strategy B TVT or TOT→ Burch→ Burch
RF-SUI strategy B RF-SUI→ Burch→ TOT or TOT
Burch strategy Burch→ TVT or TOT→ TVT or traditional
RF-SUI radiofrequency for stress urinary incontinence, TVT retropubic midurethral synthetic sling, TOT transobturator midurethral synthetic sling,
Traditional bladder-neck autologous sling, SAE serious adverse event
a Average duration over the 12-quarter simulation is the average of the number of quarters that each simulated patient went before there was a failure of
efficacy based on pad weight
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In comparing the costs of the different treatment strategies,
a gradual but persistent increase in payer cost is noted over a
3-year period as the intensity of the therapies increases. RF-
SUI strategy A has the lowest cost, at $4,100, followed by an
increase in cost with sling surgeries ranging from $5,000 to
$5,800 and culminating in the highest cost, the Burch proce-
dure, at $9,500. And although it is clear that complexity, costs,
and success rates are highly correlated, it should also be noted
that the SAE rates and costs associated with managing these
SAEs are also highly correlated. Therefore, just as the efficacy
costs of the five treatment strategies are identified in this
paper, so, too, are SAE costs of these five treatment strategies.
Again, it is clear that as complexity and costs increase, so do
costs of managing both transient and life-altering AE.
As a general prevailing philosophy, most physicians and
providers offer patients therapies with proven efficacy and try
nonsurgical treatments first. If those treatments are not success-
ful, patients and their physicians may consider more invasive,
hencemore risky, procedures. For example, that philosophy has
been outlined by the AUA for treating overactive bladder [19,
20]. It is that philosophy we used to develop strategies for
treating SUI in women who failed conservative therapy. We
compared strategies that incorporate the use of nonsurgical RF-
SUI before moving to surgery. Inclusion of RF-SUI was
expected to improve outcomes for some women without
subjecting them to surgery and to reduce overall health care
costs. The suggestion that cost savings can be identified if
physicians and patients are encouraged to follow a sequential
strategy for managing SUI first by using the least-invasive,
lower-cost, safer procedure, is supported by the findings of this
study. A recent health technology assessment by Imamura et al.
was consistent with findings that care paths that begin with
conservative, office-based treatments are more cost effective
than initial operative treatment or a rapid progression to oper-
ative therapy [21]. The application of such progressively inva-
sive treatment strategies to SUI management results in a direct
per-patient treatment savings of $1,000 over a 3-year period if
patients are treated with the least invasive therapy first.
Whereas treatment with RF-SUI may be successful for
some women, others will not have satisfactory results and will
opt for a subsequent surgical procedure. The previous use of
RF-SUI will not interfere with subsequent surgery and in fact
may improve surgical results. The lesions created during RF-
SUI treatment are microlesions within the urethra. Surgical
procedures are performed outside the urethra, and the
microlesions will not inhibit surgical success. In addition,
Appell et al. found that RF-SUI improved leak-point pressure,
which would serve to enhance the outcome of surgery [2].
Whereas some women may simply prefer noninvasive
treatments, others may be concerned over recent alerts related
to synthetic mesh. On 20 October 2008, the FDA issued a
Public Health Notification on serious complications associated
with surgical mesh placed through the vagina (transvaginal
placement) to treat POP [22]. To evaluate the safety and effec-
tiveness of surgical mesh, the FDA conducted a review of the
scientific literature from 1996 through 2011. The review con-
cluded that the use of mesh for POP repair did not improve
symptoms or QoL over traditional nonmesh repair. The review
of surgical mesh use in SUI treatment is ongoing, with an FDA
report to be issued at a later date. The AUA believes the true
incidence rate for SAEs associated with synthetic mesh is not
known [23].
The major limitations in this analysis are similar to those in
other SUI studies: absence of consistent terminology and def-
initions used to define qualitative and quantitative outcomes,
lack of a uniform and standardized definition of success, lack of
RCTs with and without blinding of the five different treatment
arms used in this analysis, variability in time horizons for
patient follow-up, and high lost-to-follow-up rate in all studies
for patients followed >1 year. The addition of qualitative or
subjective outcomemeasures was initially considered for use in
this study; however, it was discovered that these measures of
success and patient-reported outcomes also varied widely
across trials. Randomized studies would ensure that patients
undergoing surgical procedures or RF-SUI were equivalent and
that efficacy results used in this analysis were applicable to the
same types of patients. However, real-world outcomes may
vary from results observed in RCTs, which are often performed
in academic medical centers by seasoned, experienced sur-
geons. For modeling purposes, we assumed that patient char-
acteristics in the study were similar, as they were all refractory
to conservative therapy prior to more significant interventions,
such as RF-SUI, slings, or Burch procedures.
In our literature review, we selected studies that included
patients who would be candidates for RF-SUI and surgical
treatments assessed in the model. Because RF-SUI is not
recommended for patients with intrinsic sphincter deficiency
or urgency urinary incontinence, studies for those patients
were excluded. Our decision to base treatment efficacy on
the pad test was driven by the frequency and consistency with
which that test was reported in the literature. Use of the pad
test as an accepted measure of success is supported by its use
as an outcome by three major multicenter RCTs for surgical
treatments [9–12]. Although consistency of objective outcome
measures is lacking, measures tend to result in similar conclu-
sions: a procedure that is efficacious when measured with the
pad test is also efficacious when measured with leak-point
pressure. Because of that tendency, we believe our choice of
pad test for efficacy should not have biased results. However,
subjective measures of success, such as increase in QoL or
self-report diaries, may be influenced by patient expectations
and experience. Attempts to extend this analysis beyond this
3-year time horizon was limited by the absence of long-term
studies, high levels of patient fallout in the studies evaluated,
and the absence of meaningful cross-functional, quantitative
parameters by which studies could be compared. We believe
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the analysis and the 3-year time horizon used is sufficiently
robust to provide valid conclusions.
Conclusion
SUI has a profound negative effect on QoL of affected individ-
uals and a negative impact on society with increased health care
costs and decreased work productivity. SUI management strate-
gies presented here are supported by the literature and offer
physicians and health policymakers a solution for women with
SUI who want to avoid the inherent risks and recovery of
invasive continence surgery. Superior safety and cost effective-
ness are recognized when patients are offered a sequential ap-
proach to SUI management. This sequential approach is consis-
tent with treatment strategies for other conditions in a health care
environment that pursues both quality and cost effectiveness as
valuable attributes in the provision of patient care.
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